HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan. 17, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that studies have been successfully completed for the Company’s saliva version of the NicAlert(TM) test for tobacco exposure. The studies were independently undertaken in general medical settings to assess the accuracy and utility of the saliva test. The Company’s saliva test can be used without instruments and can be performed in minutes using several drops of saliva.
